Allosteric Targeting Of The Dopamine D2 Receptor: A Novel Approach For The Treatment Of Parkinson’s Disease And Schizophrenia

多巴胺 D2 受体的变构靶向：治疗帕金森病和精神分裂症的新方法

• 批准号: nhmrc : 1098424
• 负责人: Dr Ben Capuano
• 金额: $ 32.29万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/allosteric-targeting-dopamine-disease-schizophrenia/662378
• 关键词: Allosteric; Targeting; Dopamine; D2; Receptor

The dopamine D2 receptor is a brain protein that is the target for drugs that are used in the treatment of schizophrenia and Parkinson's disease (PD). In both cases the current drugs have significant side effects because they simply act to switch the receptor off or on respectively. We will focus on a new class of drugs that, because they act to tune up or tune down the activity of the D2 receptor, may be a safer more effective approach to treat these disorders.

多巴胺D2受体是一种大脑蛋白质，是用于治疗精神分裂症和帕金森病(PD)的药物的靶标。在这两种情况下，目前的药物都有明显的副作用，因为它们只是简单地分别关闭或打开受体。我们将专注于一类新的药物，因为它们的作用是调节或调节D2受体的活性，可能是治疗这些疾病的更安全、更有效的方法。